Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Analgesic effect and tolerability of alpha-methyl-4-(2-thienyl-carbonyl)phenylacetic acid (suprofen, Suprol) drops were tested in an open study including 51 informed outpatients with moderate to severe postoperative and posttraumatic pain. Suprofen drops were administered for 7 days, at doses of 33 drops (= 200 mg of suprofen) t.i.d. or q.i.d. The pain intensity was recorded prior to the treatment and after 2, 4 and 7 days; pain relief was assessed on days 2, 4 and 7. Effectiveness and tolerability were by the investigator and by the patients globally evaluated upon completion of the trial. The intensity of pain dropped within the 7-day treatment period from initially severe pain to mild. Pain relief was seen in 92% of the subjects after day 2, in 98% after day 4, and in 100% after day 7 of treatment. Investigator's and patients' final evaluation of the therapeutic effect indicated good analgesic activity in 86% of the population, and very good analgesic effect in 84%. Moderate effect was seen in 12 and 14%, respectively. The tolerability of suprofen drops was by investigator and patients considered good to very good in 82% of the cases, moderate in 16%, and poor in 1 case.
 ...
PMID:Open clinical study with suprofen drops in the treatment of postoperative and posttraumatic pain. 376 81

In a study including a total of 175 children, ranging in age from 3 months to 3 years and suffering from otitis media, the analgesic effect of alpha-methyl-4-(2-thienylcarbonyl)-phenyl acetic acid (suprofen, Suprol) syrup was compared with that of lidocaine 0.03 g/6 g + phenazone (phenyl-dimethylpyrazolone) 0.03 g/6 g (L PDP) ear drops. The study was designed as an open controlled trial. The test medications were applied in single doses: suprofen 5-7.5 mg/kg b.w., orally; (L PDP) 1 drop, locally. The severity of pain was assessed in the beginning of the treatment and 2 h following administration of the drugs. The results were indicative of the fact that in children on suprofen syrup marked pain relief was obtained, whereas the painful condition of children on L PDP ear drops even deteriorated.
 ...
PMID:Clinical experience and results of treatment with suprofen in pediatrics. 4th communication: Assessment of pain in babies and infants/Analgesic effect of suprofen syrup in otitis media. 387 75

Analgesic effect and tolerability of alpha-methyl-4-(2-thienylcarbonyl)-phenylacetic acid (suprofen, Suprol) 200 mg were compared with pentazocine 30 mg and placebo in 88 patients in moderate to severe postoperative pain. The trial was designed as a randomized single-blind study; the test drugs were in single doses (1 ml ampuls) administered by deep intragluteal injection in the upper outer quadrant. The test population was homogeneous as to anamnestic data; the initial intensity of pain was comparable in all three groups. Statistical analysis of the obtained data revealed that at the rating times 30 min to 3 h suprofen was statistically significantly superior to placebo, while after 2 h it was significantly superior to pentazocine. The investigator's final global appreciation of effectiveness states moderate to good effect in 86% of the patients on suprofen, 76% of those on pentazocine, and 63% of the subjects on placebo. Significant difference existed only between suprofen and placebo. Systemic tolerability was considered good to very good in 97% of the subjects in all three treatment groups, whereas local tolerability was considered poor in 2 patients (6.9%) in the group on suprofen. There were no significant differences between the medications. Two subjects each on suprofen and pentazocine and 1 patient on placebo experienced side effects.
 ...
PMID:Clinically controlled comparative study of suprofen, pentazocine, and placebo. Experience with intramuscular single doses. 389 44

In the present randomized single-blind study local and systemic tolerability of alpha-methyl-4-(2-thienylcarbonyl)-phenyl acetic acid (suprofen, Suprol) 200 mg/ml i.m. were compared with those of diclofenac 25 mg/ml and placebo. The three treatment groups consisted of 15 patients each and were homogeneous with respect to demographic parameters. The volunteers were assigned to these groups in random fashion and underwent treatment with 3 injections/day of either suprofen or diclofenac or placebo for 7 days. Mild local pain or systemic intolerance signs were equally rare in all three groups. The laboratory tests with the three preparations studied failed to indicate any negative influence on the hematopoietic organs or the adrenal activity. Abnormal changes in the ECG and the cardiovascular parameters during the treatment were not observed. Moderately or slightly elevated SGOT and SGPT values were seen during treatment with suprofen; however, these values returned to normal after the treatment. As compared with these elevations the values for subjects on diclofenac were higher and did not return to normal within 5 days following withdrawal of the drug. Moreover, the creatine phosphokinase activity, observed in both the suprofen and the diclofenac group, was so extremely high in subjects on diclofenac that this drug had to extremely high in subjects on diclofenac that this drug had to be withdrawn on day 4 of the study. On the basis of these results it can be stated that intramuscular injections of suprofen 200 mg/ml are locally and systemically well tolerated even on administration t.i.d. Measurement of the steady-state plasma level was not indicative of altered kinetic behaviour of suprofen. The plasma levels remained constant.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Pharmacokinetics and tolerability of suprofen. Experience with intramuscular application in healthy volunteers. 401 40

Local and systemic tolerability of alpha-methyl-4-(2-thienylcarbonyl)-phenyl acetic acid (suprofen, Suprol 200 mg/ml intravenous injection and suprofen 200 mg/ml infusion were in the present single-blind crossover study assessed and compared with those of placebo i.v. 12 volunteers each were in random fashion assigned to one of the three treatment groups; for a period of 7 days the subjects received daily 2 intravenous injections or infusions of suprofen or placebo, respectively. Investigator and patients appreciation of local tolerability revealed that no pain or discomfort occurred in 98% of the subjects on suprofen and in 100% of those on placebo. The incidence of limited, moderate or mild, adverse reactions was in the suprofen group higher than in the placebo group. The laboratory tests for the treatment groups indicated no negative effects on either the hematopoietic organs or the liver function; no abnormal changes in ECG and cardiovascular parameters were observed during the treatment period. Tests of the renal parameters, i.e., creatinine clearance, creatinine, and urea (BUN), revealed negative shifts in the first two parameters, whereas BUN remained uninfluenced. On the basis of these results it can be stated that 200 mg/ml of suprofen, given either as intravenous injection or as infusion, were both locally and systemically well tolerated even on administration b.i.d. The more or less unfavorable shifts in the renal parameters, which occurred with placebo as well as with suprofen, require further investigation.
 ...
PMID:Local and systemic tolerability of suprofen. Experience with intravenous administration and infusion in healthy volunteers (1st comm.). 401 41

The present randomized double-blind study was performed to investigate the analgesic effects of single doses of suprofen (alpha-methyl-4-(2-thienylcarbonyl)benzene acetic acid; Suprol) 200 mg, suprofen 400 mg paracetamol (APAP, acetaminophen) 650 mg, and combination suprofen 100 mg + APAP 650 mg versus placebo. The five treatment groups were homogeneous as to their demographic features and comprised 28--32 subjects each. Data for a total of 146 patients were evaluated. There were statistically significant differences between the therapeutic effect of the test preparations containing active substance on the one hand and placebo and the other hand. Of the active substances, the best results were obtained with the combination suprofen 100 mg + APAP 650 mg, followed by suprofen 400 mg and APAP 650 mg; there were hardly any differences in the results obtained with the two latter substances. Suprofen 200 mg ranked third. Statistical significance was only seen for the parameter pain intensity (SPID) on comparison of suprofen 100 mg + APAP 650 mg versus suprofen 200 mg. Side effects, homogeneously distributed over the treatment groups, were observed in four cases.
 ...
PMID:[Treatment of postoperative wound pain with suprofen]. 635 7

In a single-dose, double-blind randomized study, the analgesic efficacy of suprofen 200, suprofen (alpha-methyl-4-(2-thienylcarbonyl)-benzene acetic acid; Suprol) 400 mg and diflunisal 750 mg capsules was determined in comparison to placebo capsules. A total of 130 patients participated in the study, all of them requiring analgesic treatment on the first post-operative day following meniscectomy. The treatment groups were homogeneous with respect to their demographic data. With the chosen pain model all active test substances were statistically significantly superior to placebo as far as pain intensity differences (SPID), pain relief (TOTPAR) and global evaluation of efficacy were concerned. Despite great differences in dosage and half-life, the active test substances must be regarded as equipment. Side effects were reported by 2 patients each in the diflunisal 750 mg and the placebo group, and by 1 patient treated with suprofen 200 mg.
 ...
PMID:[A controlled clinical single-dose comparative study of suprofen and diflunisal]. 635 8

A single-dose, double-blind study included a total of 196 patients with neurologic pain. The subjects were subdivided into five groups and treated with alpha-methyl-4-(2-thienylcarbonyl) benzene acetic acid (suprofen, Suprol) 400 mg; suprofen 200 mg acetylsalicylic acid (ASA) 650 mg; ASA 650 plus codeine 60 mg; and placebo. The population was homogeneous as to age, sex, and body weight. About 95% of the patients rated the intensity of pain severe prior to treatment. The clinical effect was appreciated by investigator and patients after up to 6 h following administration of the single dose. It was demonstrated that the active substances all were significantly superior to placebo in all criteria tested. Statistical analysis of the parameters investigated revealed the following order of effectiveness of the test medications: Suprofen 400 and 200, respectively, = ASA 650 + codeine 60 greater than ASA 650 greater than placebo. The final overall patients appreciation of effectiveness showed good to very good results in 97.4% of the patients on suprofen 400; 65% of those on suprofen 200; 72.5% of those on ASA 650 + codeine 60; 13.5% of those on ASA 650; and 7.5% of those on placebo. During the treatment 26 patients experienced adverse reactions; of these, 18 subjects on ASA 650 + codeine 60 complained of fatigue or somnolence as the side effect experienced most frequently.
 ...
PMID:[Experience with suprofen for acute and chronic pain in neurologic practice]. 635 9

Indomethacin is still used commonly for the treatment of rheumatic diseases but is associated with side effects, particularly headache, in a number of patients. A controlled or sustained release formulation of indomethacin might provide lower peak plasma levels and thus reduce side effects while still maintaining adequate plasma levels to control pain and inflammation. In this single dose crossover study, normal volunteers received the new formulation of indomethacin (Indocid GITS 6/85) fasting or with a standard meal, indomethacin 75 mg with a standard meal or indomethacin 25 mg three times daily with a standard meal. Plasma concentration data showed that peak plasma levels were reduced but the area under the plasma concentration curve was not significantly different between the four treatments.
 ...
PMID:Pharmacokinetics of an osmotically controlled delivery indomethacin preparation in normal volunteers. 662 54

Nonsteroidal anti-inflammatory drugs (NSAIDs) produce potent analgesic, antipyretic, and anti-inflammatory effects. We studied postoperative pain in 97 consecutive patients having photorefractive keratectomy (PRK) by an excimer laser with different topical NSAID protocols. Treatment with topical homatropine hydrobromide, either diclofenac sodium (Voltaren Ophthalmic) or ketorolac tromethamine (Acular), and a soft contact lens was most effective in achieving post-PRK analgesia. We also studied post-PRK myopic regression in 68 consecutive patients and found that flurbiprofen sodium (Ocufen), when added to topical steroid protocols, significantly reduced myopic regression for one year postoperatively more than steroids alone or steroids and diclofenac sodium. Diclofenac, used with topical steroids, had less of an additive effect on myopic regression than did flurbiprofen. Topical NSAIDs are useful adjuncts to PRK therapy, both to eliminate postoperative pain and to control post-PRK myopic regression.
 ...
PMID:Use of topical nonsteroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy. 800 90


<< Previous 1 2 3 Next >>